Studies energy use in heart and muscle during exercise in heart failure
Studies whether muscle energy changes relate to exercise limits in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Exercise Intolerance in Heart Failure
Key facts
- Where
- Baltimore, United StatesSee the site
Where in United States
- Johns Hopkins HospitalBaltimore, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT03775577
- Record updated
- 9 March 2026
- Original description
The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.Read full original descriptionShow less
Exercise Intolerance in Heart Failure: the Role of Altered Cardiac and Skeletal Muscle Energetics
The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.
Inclusion: Patients of either gender who are greater than 21 years of age (no upper age limit),; Permission of patient's clinical attending physician,; Previous clinical diagnosis of HF with current New York Heart Association (NYHA) Class II-III symptoms for at least 1 month,; Left ventricular ejection fraction (EF) >50% by echocardiography, MRI, CT or x-ray or nuclear ventriculography within prior 12 months,; Stable medical therapy for at least 30 days (no addition or removal or major (>100%) dose change of Renin-Angiotensin-Aldosterone System (RAAS) antagonists, beta-blockers, or calcium channel blockers for hypertension).
Exclusion: History of clinical CAD or significant epicardial coronary disease (>50% stenosis) in major coronary artery by x-ray or CT angiography unless (a) the patient underwent prior successful revascularization with percutaneous coronary angioplasty within the prior three years and (b) there are no residual lesions of >50% on the most recent coronary angiographic study; Contraindications to MRI such as implanted metallic objects (pre-existing cardiac pacemakers, cerebral clips) or indwelling metallic projectiles,; History of infiltrative cardiomyopathy or constrictive pericarditis,; Significant pulmonary disease,; Any condition other than HF which could limit the ability to perform a 6MW or cardiopulmonary exercise test (CPET) test (e.g., critical peripheral vascular disease, significant orthopedic or neurological conditions),; Any diseases other than HF which are likely to significantly alter the patient's global perception of status or quality of life over a period of 6 months; Significant peripheral vascular disease; Estimated glomerular filtration rate (eGFR) <20ml/min,; Unable to understand the risks, benefits, and alternatives of participation and give meaningful consent,; Significant valvular abnormalities,; Pregnant women (women of childbearing potential will undergo blood or urine pregnancy testing),; Cor pulmonale,.